REGN · News · 20260809N

Product / Drug Pipeline Progress

REGENERON PHARMACEUTICALS, INC. · 2026-08-09 · Importance 41 · Surprise 42

Third-party reports describe securities litigation alleging that Regeneron’s Phase III aflibercept study used flawed preliminary statistical assumptions and lacked meaningful differentiation from standard therapies. A separate report identifies the failed Phase III Fianlimab-Libtayo study, which did not achieve statistical significance on its primary endpoint. The reports indicate that the clinical setbacks affected investors who purchased Regeneron securities during periods spanning August 2023 through May 2026.

Key facts

• The Faruqi notice alleges Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which ultimately failed to reach statistical significance. source